Neurologists pass on Aduhelm again. Most agree with CMS decision to limit coverage, study finds
A majority of neurologists agree with Medicare on the need for more data on Biogen and Eisai’s Alzheimer’s disease med Aduhelm, despite FDA approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
